Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Remodeling01:40

Bone Remodeling

40.2K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.2K
Bone Disorders01:29

Bone Disorders

5.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.0K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.8K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

3.6K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.6K
What is the Skeletal System?01:02

What is the Skeletal System?

56.6K
Overview
56.6K
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

5.0K
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and risk factors for falls in older men and women: The English Longitudinal Study of Ageing.

Age and ageing·2016
Same author

Recent advances in the pathogenesis and treatment of osteoporosis.

Clinical medicine (London, England)·2016
Same author

A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Archives of osteoporosis·2016
Same author

On epidemiology of fractures and variation with age and ethnicity.

Bone·2016
Same author

Pubertal timing and bone phenotype in early old age: findings from a British birth cohort study.

International journal of epidemiology·2016
Same author

Anti-Osteoporosis Medication Prescriptions and Incidence of Subsequent Fracture Among Primary Hip Fracture Patients in England and Wales: An Interrupted Time-Series Analysis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2016
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Related Experiment Videos

Osteoporosis.

Philip Sambrook1, Cyrus Cooper

  • 1Institute of Bone and Joint Research, University of Sydney, Sydney 2065, NSW, Australia. sambrook@med.usyd.edu.au

Lancet (London, England)
|June 20, 2006
PubMed
Summary
This summary is machine-generated.

Osteoporosis management is advancing, shifting towards absolute fracture risk assessment and wider use of bone turnover markers. Bisphosphonates remain key, with ongoing research into optimal treatment duration and novel biological agents.

Related Experiment Videos

Area of Science:

  • Endocrinology
  • Gerontology
  • Public Health

Background:

  • Osteoporosis represents a significant global health concern.
  • Recent years have yielded substantial progress in understanding osteoporosis's epidemiology, pathophysiology, and treatment modalities.
  • Continuous advancements are rapidly shaping the field.

Purpose of the Study:

  • To review the evolving landscape of osteoporosis diagnosis and treatment.
  • To highlight the anticipated shifts in clinical assessment and therapeutic strategies.

Main Methods:

  • Review of recent literature and clinical practice trends in osteoporosis.
  • Analysis of emerging diagnostic tools and therapeutic agents.

Main Results:

  • Clinical assessment is likely to transition from bone densitometry alone to algorithms incorporating absolute fracture risk.
  • Biochemical markers of bone turnover are expected to gain broader clinical application.
  • Bisphosphonates are anticipated to remain the primary therapy, with emphasis on optimizing suppression levels and treatment duration.

Conclusions:

  • Future osteoporosis care will likely integrate advanced risk assessment tools and novel therapeutic options, including biologics.
  • Continued research is crucial for refining treatment strategies and understanding optimal therapy duration and intensity.